Literature DB >> 2039198

Pseudomonas pseudomallei, a common pathogen in Thailand that is resistant to the bactericidal effects of many antibiotics.

T Sookpranee1, M Sookpranee, M A Mellencamp, L C Preheim.   

Abstract

The purpose of this investigation was to identify newer antimicrobial agents that may be useful in the therapy of melioidosis. The in vitro susceptibilities of 199 clinical isolates of Pseudomonas pseudomallei to 22 antibiotics were determined by standard disk diffusion, and those to 13 antibiotics were determined by agar dilution. Over 90% of the isolates were susceptible to imipenem, piperacillin-tazobactam, piperacillin, ceftazidime, ticarcillin-clavulanate, ampicillin-sulbactam, and carumonam by both methods. Standard disk diffusion yielded unacceptably high false-susceptibility results with aztreonam, ciprofloxacin, and temafloxacin. Piperacillin, ceftazidime, imipenem, and ciprofloxacin were not bactericidal for three selected P. pseudomallei strains as determined by time-kill curve methods. Furthermore, addition of ciprofloxacin to piperacillin, ceftazidime, or imipenem did not enhance bactericidal activity. One hundred ninety-four strains showed weak beta-lactamase production that did not increase upon incubation with cefoxitin. These findings suggest that several newer antimicrobial agents may prove useful in the treatment of melioidosis. However, results of susceptibility studies involving P. pseudomallei and newer agents must be interpreted with caution.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2039198      PMCID: PMC245036          DOI: 10.1128/AAC.35.3.484

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Melioidosis: pathogenesis and immunity in mice and hamsters. II. Studies with avirulent strains of Malleomyces pseudomallei.

Authors:  A M DANNENBERG; E M SCOTT
Journal:  Am J Pathol       Date:  1958 Nov-Dec       Impact factor: 4.307

2.  beta-Lactamase of Pseudomonas pseudomallei and its contribution to antibiotic resistance.

Authors:  D M Livermore; P Y Chau; A I Wong; Y K Leung
Journal:  J Antimicrob Chemother       Date:  1987-09       Impact factor: 5.790

3.  In vitro susceptibility of strains of Pseudomonas pseudomallei isolated in Thailand and Hong Kong to some newer beta-lactam antibiotics and quinolone derivatives.

Authors:  P Y Chau; W S Ng; Y K Leung; S Lolekha
Journal:  J Infect Dis       Date:  1986-01       Impact factor: 5.226

4.  Pseudomonas pseudomallei: susceptibility to chemotherapeutic agents.

Authors:  T C Eickhoff; J V Bennett; P S Hayes; J Feeley
Journal:  J Infect Dis       Date:  1970-02       Impact factor: 5.226

5.  In vitro activities of the newer beta-lactam and quinolone antimicrobial agents against Pseudomonas pseudomallei.

Authors:  L R Ashdown
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

6.  In vitro activity of various cephalosporins against Pseudomonas pseudomallei.

Authors:  L R Ashdown; R J Frettingham
Journal:  J Infect Dis       Date:  1984-11       Impact factor: 5.226

Review 7.  The pseudomallei group: a review.

Authors:  C Howe; A Sampath; M Spotnitz
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

Review 8.  Recent developments in beta-lactamase research and their implications for the future.

Authors:  K Bush
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

9.  Survival of Pseudomonas pseudomallei in human phagocytes.

Authors:  S Pruksachartvuthi; N Aswapokee; K Thankerngpol
Journal:  J Med Microbiol       Date:  1990-02       Impact factor: 2.472

10.  Susceptibility in vitro and in vivo of Pseudomonas pseudomallei to rifampin and tetracyclines.

Authors:  M W Fisher; A B Hillegas; P L Nazeeri
Journal:  Appl Microbiol       Date:  1971-07
View more
  6 in total

1.  Multicenter prospective randomized trial comparing ceftazidime plus co-trimoxazole with chloramphenicol plus doxycycline and co-trimoxazole for treatment of severe melioidosis.

Authors:  M Sookpranee; P Boonma; W Susaengrat; K Bhuripanyo; S Punyagupta
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 2.  Melioidosis: epidemiology, pathophysiology, and management.

Authors:  Allen C Cheng; Bart J Currie
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

3.  Localization of penicillin-binding proteins to the splitting system of Staphylococcus aureus septa by using a mercury-penicillin V derivative.

Authors:  T R Paul; A Venter; L C Blaszczak; T R Parr; H Labischinski; T J Beveridge
Journal:  J Bacteriol       Date:  1995-07       Impact factor: 3.490

Review 4.  Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

Review 5.  Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C P Rains; H M Bryson; D H Peters
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

6.  Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei Infection, 2010.

Authors:  Rebecca Lipsitz; Susan Garges; Rosemarie Aurigemma; Prasith Baccam; David D Blaney; Allen C Cheng; Bart J Currie; David Dance; Jay E Gee; Joseph Larsen; Direk Limmathurotsakul; Meredith G Morrow; Robert Norton; Elizabeth O'Mara; Sharon J Peacock; Nicki Pesik; L Paige Rogers; Herbert P Schweizer; Ivo Steinmetz; Gladys Tan; Patrick Tan; W Joost Wiersinga; Vanaporn Wuthiekanun; Theresa L Smith
Journal:  Emerg Infect Dis       Date:  2012-12       Impact factor: 6.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.